| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,200,000 |
| Market
Cap: |
56.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9001 - $1.54 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 4.7 |
| Insider 3/6 Months : 5.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Chimerix is a biopharmaceutical company focused on developing medicines that improve and extend the lives of patients facing deadly diseases. The U.S. Food and Drug Administration (FDA) approved TEMBEXA (brincidofovir) for the treatment of smallpox as a medical countermeasure. Co.'s two clinical-stage development programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead indication. DSTAT is in Phase 3 development as a potential first-line therapy in combination with standard chemotherapy for the treatment of acute myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
20,000 |
205,450 |
301,850 |
| Total Buy Value |
$0 |
$19,011 |
$225,404 |
$392,675 |
| Total People Bought |
0 |
1 |
5 |
5 |
| Total Buy Transactions |
0 |
2 |
7 |
13 |
| Total Shares Sold |
6,344 |
6,344 |
9,954 |
17,584 |
| Total Sell Value |
$6,609 |
$6,609 |
$10,193 |
$24,064 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
3 |
3 |
4 |
6 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Laspaluto Michelle |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-14 |
4 |
AS |
$1.04 |
$2,023 |
D/D |
(1,940) |
110,999 |
|
-16% |
|
| Jakeman David |
VP OF FINANCE AND ACCOUNTING |
• – – |
2024-02-14 |
4 |
AS |
$1.04 |
$2,777 |
D/D |
(2,660) |
141,232 |
|
-16% |
|
| Andriole Michael T. |
PRESIDENT AND CEO |
• • – |
2024-02-14 |
4 |
AS |
$1.04 |
$1,809 |
D/D |
(1,744) |
447,021 |
|
-16% |
|
| Andriole Michael T. |
PRESIDENT AND CEO |
• • – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
83,750 |
448,765 |
|
- |
|
| Laspaluto Michelle |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
112,939 |
|
- |
|
| Melemed Allen S. |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,125 |
86,430 |
|
- |
|
| Alrutz Michael A |
SVP AND GENERAL COUNSEL |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
21,875 |
168,098 |
|
- |
|
| Jakeman David |
VP OF FINANCE AND ACCOUNTING |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,750 |
143,892 |
|
- |
|
| Andriole Michael T. |
President and CEO |
• • – |
2023-12-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
17,000 |
365,015 |
|
- |
|
| Laspaluto Michelle |
Chief Financial OfficerOfficer |
• – – |
2023-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
87,939 |
|
-5% |
|
| Middleton Fred A |
Director |
– • – |
2023-11-17 |
4 |
B |
$0.96 |
$16,522 |
I/I |
17,295 |
100,000 |
2.1 |
8% |
|
| Middleton Fred A |
Director |
– • – |
2023-11-10 |
4 |
B |
$0.92 |
$2,489 |
I/I |
2,705 |
82,705 |
2.02 |
6% |
|
| Jakeman David |
VP of Finance and Accounting |
• – – |
2023-09-28 |
4 |
AS |
$0.99 |
$3,584 |
D/D |
(3,610) |
133,142 |
|
-5% |
|
| Middleton Fred A |
Director |
– • – |
2023-09-25 |
4 |
B |
$0.98 |
$19,636 |
I/I |
20,000 |
80,000 |
2.1 |
-5% |
|
| Andriole Michael T. |
President and CEO |
• • – |
2023-08-01 |
4 |
A |
$1.19 |
$29,750 |
D/D |
25,000 |
382,015 |
|
- |
|
| Andriole Michael T. |
Chief Business Officer and CFO |
• – – |
2023-05-18 |
4 |
B |
$1.14 |
$59,150 |
D/D |
51,700 |
357,015 |
2.74 |
-10% |
|
| Sherman Michael A. |
Chief Executive Officer |
• • – |
2023-05-12 |
4 |
B |
$1.12 |
$97,652 |
I/I |
87,000 |
87,000 |
2.66 |
-7% |
|
| Demski Martha J |
Director |
– • – |
2023-05-10 |
4 |
B |
$1.11 |
$19,980 |
I/I |
18,000 |
72,055 |
2.1 |
-6% |
|
| Meyer Robert J. |
Director |
– • – |
2023-05-08 |
4 |
B |
$1.14 |
$9,975 |
D/D |
8,750 |
35,150 |
2.39 |
-7% |
|
| Middleton Fred A |
Director |
– • – |
2023-03-28 |
4 |
B |
$1.21 |
$24,152 |
I/I |
20,000 |
60,000 |
2.1 |
-11% |
|
| Jakeman David |
Principal Accounting Officer |
• – – |
2023-01-26 |
4 |
AS |
$1.76 |
$5,686 |
D/D |
(3,230) |
136,752 |
|
-13% |
|
| Andriole Michael T. |
Chief Business Officer and CFO |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
32,175 |
294,899 |
|
- |
|
| Jakeman David |
Principal Accounting Officer |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
12,450 |
139,982 |
|
- |
|
| Alrutz Michael A |
Principal Executive Officer |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
21,450 |
142,015 |
|
- |
|
| Melemed Allen S. |
Chief Medical Officer |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
25,740 |
47,887 |
|
- |
|
299 Records found
|
|
Page 1 of 12 |
|
|
0.02 (2.09%) 
